Beta-glucan-CRM197 conjugates as candidates antifungal vaccines

Vaccine

Volumn 28, Issue 14, 2010, Pages 2615-2623

  Bromuro, Carla ^a   Romano, Maria ^b   Chiani, Paola ^a   Berti, Francesco ^b   Tontini, Marta ^b   Proietti, Daniela ^b   Mori, Elena ^b   Torosantucci, Antonella ^a   Costantino, Paolo ^b   Rappuoli, Rino ^b   Cassone, Antonio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Glucan; Adjuvant; Antifungal antibody; Antifungal vaccine

Indexed keywords

ADJUVANT; BETA 1,6 GLUCAN; BETA GLUCAN; CURDLAN; DIPHTHERIA TOXOID CRM197; FUNGUS VACCINE; IMMUNOGLOBULIN ANTIBODY; LAMINARAN; OLIGOSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; INFECTION PREVENTION; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, FUNGAL; BACTERIAL PROTEINS; BETA-GLUCANS; FEMALE; FUNGAL VACCINES; HUMANS; IMMUNOGLOBULIN G; MICE; MYCOSES; SURVIVAL ANALYSIS; VACCINES, CONJUGATE;

EID: 77649339396     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.012     Document Type: Article

References (42)

1. Meersseman W., Vandecasteele S.J., Wilmer A., Verbeken E., Peetermans W.E., and Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 170 (2004) 621-625
2. Pagano L., Caira M., Nosari A., Van Lint M.T., Candoni A., Offidani M., et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 45 (2007) 1161-1170
3. Cornillet A., Camus C., Nimubona S., Gandemer V., Tattevin P., Belleguic C., et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 43 (2006) 577-578
4. McNeil M.M., Nash S.L., Hajjeh R.A., Phelan M.A., Conn L.A., Plikaytis B.D., et al. Trends in moratality due to invasive mycotic diseases in the United States. CID 33 (2001) 641-647
5. Pfaller M.A., and Diekema D.J. Epidemiology of invasive candidiasis: a persistence public health problem. Clin Microbiol Rev 20 (2007) 133-163
6. Wisplinghoff H., Bishoff T., Tallent S.M., Seifert H., Wenzel R.P., and Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. CID 39 (2004) 309-317
7. Pfaller M.A., Pappas P.G., and Wingard J.P. Invasive fungal pathogens: current epidemiology trends. CID 43 S1 (2006) S3-14
8. Cassone A. Fungal vaccines: real progress from real challenges. Lancet Infect Dis 8 (2008) 114-124
9. Cutler J.E., Deepe Jr. G.S., and Klein B.S. Advances in combating fungal diseases: vaccine on the threshold. Nat Rev Microbiol 5 (2007) 13-28
10. Cassone A., and Torosantucci A. Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine. Expert Rev Vaccines 5 (2006) 859-867
11. Dan J.M., and Levitz S.M. Prospects for development of vaccines against fungal diseases. Drug Resist Updat 9 (2006) 105-110
12. Mochon A.B., and Cutler J.E. Is a vaccine needed against Candida albicans?. Med Mycol 43 (2005) 97-115
13. Bowman S.M., and Free S.J. The structure and synthesis of the fungal cell wall. BioEssays 28 (2006) 799-808
14. Masuoka J. Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges. Clin Microbiol Rev 17 (2004) 281-310
15. Bromuro C., Torosantucci A., Chiani P., Conti S., Polonelli L., and Cassone A. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect Immun 70 (2002) 5462-5470
16. Giannini G., Rappuoli R., and Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res 25 12 (1984) 4063-4069
17. Torosantucci A., Bromuro C., Chiani P., De Bernardis F., Berti F., Galli C., et al. A novel glyco-conjugate vaccine against fungal pathogens. JEM 202 (2005) 597-606
18. Read S.M., Currie G., and Bacic A. Analysis of the structural heterogeneity of laminarin by electrospray-ionisation-mass spectrometry. Carbohydr Res 281 (1996) 187-201
19. Torosantucci A., Chiani P., Bromuro C., De Bernardis F., Palma A.S., Liu Y., et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One 4 (2009) e5392.4:e5392
20. Scott R.W., Moore W.E., Effland M.J., and Millett M.A. Ultraviolet spectrophotometric determination of hexoses, pentoses, and uronic acids after their reactions with concentrated sulfuric acid. Anal Biochem 21 1 (1967) 68-80
21. Park J.T., and Johnson M.J. A submicrodetermination of glucose. J Biol Chem 181 (1949) 149-151
22. Habeeb A.F. Determination of free amino groups in proteins by trinitrobenzensulfonic acid. Anal Biochem 14 (1966) 328-338
23. Miron T., and Wilcheck M. A spectrophotometric assay for soluble and immobilized N-hydroxysuccinimido esters. Anal Biochem 126 (1982) 433-435
24. Rachini A., Pietrella D., Lupo P., Torosantucci A., Chiani P., Bromuro C., et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun 75 (2007) 5085-5094
25. Kim Y.T., Kim E.H., Cheong C., Williams D.L., Kim C.W., and Lim S.T. Structural characterization of β-D-beta-D-(1 --> 3, 1 --> 6)-linked glucans using NMR spectroscopy. Carbohydr Res 328 (2000) 331-341
26. McIntosh M., Stone B.A., and Stanisich V.A. Curdlan and other bacterial (1 --> 3)-β-D-glucans. Appl Microbiol Biotechnol 68 (2005) 163-173
27. Han Y., Kanbe T., Cherniak R., and Cutler J. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect Immun 65 (1997) 4100-4107
28. Wu X., and Bundle D.R. Synthesis of glycoconjugates vaccines for Candida albicans using novel linker methodology. J Org Chem 70 (2005) 7381-7388
29. Wu X., Lipinski T., Carrel F.R., Bailey J., and Bundle D.R. Synthesis and immunochemical studies on a Candida albicans cluster glycoconjugate vaccine. Org Biomol Chem 5 (2007) 3477-3485
30. Xin H., Dziadek S., Bunde D.R., and Cutler J. Synthetic glycopeptides vaccines combining mannan and peptide epitope induce protection against candidiasis. PNAS 105 (2008) 13526-13531
31. Bystrický S., Paulovičová E., and Machová E. Candida albicans mannan-protein conjugate as vaccine candidate. Immunol Lett 85 (2003) 251-255
32. Han Y., Ulrich M.A., and Cutler J.E. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J Infect Dis 179 (1999) 1477-1484
33. Suzuki S. Immunochemical study on mannans of genus Candida. I. Structural investigation of antigenic factors 1, 4, 5, 6, 8, 9, 11, 13, 13b and 34. Curr Top Med Mycol 8 (1997) 57-70
34. Cutler J.E., and Kanbe T. Antigenic variability of Candida albicans cell surface. Curr Top Med Mycol 5 (1993) 27-47
35. Nather K., and Munro C.A. Generating cell surface diversity in Candida albicans and other fungal pathogens. FEMS Microbiol Lett 285 (2008) 137-145
36. Calcedo R., Lariño E., Calvo E., Rementería A., Sevilla M.J., Pontón J., et al. Differences in the Candida albicans antigenic expression after heat shock and infection. Rev Iberoam Micol 18 (2001) 6-11
37. Brown G.D., and Gordon S. Fungal beta-glucans and mammalian immunity. Immunity 19 (2003) 311-315
38. Schultze V., D'Agosto V., Wack A., Novicki D., Zorn J., and Hennig R. Safety of MF59 adjuvant. Vaccine 26 (2008) 3209-3222
39. Singh M., Ugozzoli M., Kazzaz J., Chesko J., Soenawan E., Mannucci D., et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 24 (2006) 1680-1686
40. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 (2008) 552-561
41. Granoff D.M., McHugh Y.E., Raff H.V., Mokatrin A.S., and Van Nest G.A. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine. Infect Immun 65 (1997) 1710-1715
42. Chiani P., Bromuro C., Cassone A., and Torosantucci A. Anti-beta-glucan antibodies in healthy human subjects. Vaccine 27 (2009) 513-519